None listed
Conditions
Interventions
Drug, Medical Device : - medication and acupuncture treatment group : medication + acupuncture treatment(three times per week. total 12 times for 4 weeks)
the location and debth of acupoint is Naegwan
Sponsors
Comprehensive and Integrative Medical Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals between the ages of 20 and 70 years 2. Individuals who meet the Rome III FD criteria: 1) Patients with one or more of these symptoms (such as postprandial fullness, early satiation, or epigastric pain or burnin g) will be considered patients with dyspepsia. If patients with typical FD symptoms have heart burn, acid regurgitation, abdominal bloating, nausea, vomiting, or belching, this could not exceed at frequency of one epidode per week. 2) Individuals with epigastric pain or burning more than once a week and they check more than three points on the visual analogue scale (VAS) for dyspeptic symptoms. 3) Individuals with postprandial fullness or early satiation more than twice a week. 3. Patients were required to have a negative upper endoscopy which excluded esophagitis, peptic ulcer disease and esophageal or gastric neoplasia. The endoscopy was required to be completed within 6 month prior to enrolment. 4. Individuals who voluntarily agree with a study protocol and sign a written informed consent
Exclusion criteria
Exclusion criteria: 1. Individuals who have peptic ulcer, erosive gastritis, acute hemorrhagic gastritis, reflux esophagitis, esophageal cancer or gastric cancer confirmed by upper GI endoscopy. 2. Individuals who have had surgery related with the gastrointestinal tract, except for appendectomy and hysterectomy. 3. Individuals who have serious structural gastrointestinal disease (gastrointestinal bleeding, mechanical obstruction, perforation of gastrointestinal tract) within the last two years. 4. Individuals who are taking drugs which might affect the gastrointestinal tract motility and function; a minimum wash-out period of one week is required before participating in the trial. 5. Individuals who have serious diseases of the cardiovascular, hepatic, renal or brain disease; prolactin secreting pituitary adenoma, liver cirrhosis, chronic renal failure, congestive heart failure. 6. Individuals who are pregnant, breastfeeding or women of child bearing age who don’t do it for birth control. 7. Individuals who have acute narrow-angle glaucoma, myasthenia gravis or acute myocardial infarction. 8. Individuals who have active psychiatric disease or alcoholism. 9. Individuals who have underweight or obesity; body mass index is less than 18 kg/m2 or more than 30 kg/m2 10. Individuals with anticoagulant therapy 11. Individuals with dyspeptic symptoms who received herbal medicine or acupuncture terapy in the 3 months before enrolment. 12. Other exclusion criteria included patients with any clinically abnormalities, if judged inappropriate for participating this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proportion of responders with adequate symptom relief | — |
Secondary
| Measure | Time frame |
|---|---|
| FD- related quality of life;individual symptom score;hospital anxiety depression;patient’s compliance;adverse event;recurrence frequency of FD symptoms | — |
Countries
Korea, Republic of
Contacts
Public ContactJoong Goo Kwon
Daegu Catholic Univercity Medical Center
Outcome results
None listed